Scaling AI in Life Sciences: Why Data Infrastructure Determines Success
According to Deloitte’s 2026 Life Sciences Outlook, only around 22% of life sciences leaders have successfully scaled AI across their organizations and a mere 9% have achieved significant financial returns from it [1]. The gap between a promising pilot and a production-grade system is rarely about algorithms. It is almost always about infrastructure.
This article explores why scaling AI in life sciences is fundamentally an engineering challenge, and what organizations need to build before they can expect AI to deliver consistent value.
The Real Bottleneck: Data Spaghetti
In most pharmaceutical and CRO environments, life sciences data infrastructure is fragmented across legacy laboratory information management systems (LIMS), clinical platforms, and external repositories. Each source may use different formats, naming conventions, metadata standards, and quality controls. Some datasets are well documented. Others are understood only by the team that originally generated them.
This creates what many teams informally call data spaghetti: a tangled environment where data exists, but cannot be reliably connected, interpreted, or reused at scale.
For AI in life sciences, this is a serious problem. Models learn from the structure and assumptions embedded in data. If the data is incomplete, poorly labeled, or affected by uncontrolled batch effects, the model may learn technical artifacts instead of meaningful biological patterns.
In single-cell omics, for example, preprocessing choices and batch correction methods can materially shift downstream gene-importance profiles, causing models to rationalize technical noise as biological insight [2]. In imaging workflows, differences in instruments, staining protocols, or acquisition settings may corrupt the signal a model learns. The breakthrough of AlphaFold was only possible because it was built on decades of curated structural data from the Protein Data Bank (PDB) – one of the most complete and consistently annotated scientific databases in existence [9]. Without that kind of foundation, even sophisticated models generate misleading results.
AI-Ready Data: Computable, Not Just Stored
Many organizations begin by trying to standardize their data. Standardization helps, but it is only part of the work. For AI to scale, data needs to become computable.
As defined by the European Molecular Biology Laboratory (EMBL), computable data is “data which has appropriate meta-data and knowledge enrichment; and that is standards-based, structured and complete, deployed in a scalable manner” [2]. This definition captures what AI-ready data actually requires in practice: interpretability by machines with minimal manual intervention.
In practical terms, teams working on life sciences data infrastructure need to be able to answer the following questions about every dataset:
- Where did the data come from?
- How was it generated and by whom?
- What transformations were applied?
- Which version is currently in use?
- What quality checks were performed?
- What is this data suitable for?
- What limitations should be considered?
This context matters because life sciences data is rarely self-explanatory. A gene expression matrix, microscopy image, or assay result may be technically readable but scientifically ambiguous without the right metadata and experimental context.
AI-ready data is therefore a managed product, one that needs ownership, documentation, quality control, and lifecycle management. Building this kind of AI drug discovery infrastructure and clinical data foundation is what separates organizations that can scale from those that keep running pilots [3].
From Pilots to Production: The MLOps Gap
A successful AI pilot can be built with a small team, a defined dataset, and a controlled objective. A production-grade AI system needs to operate under changing real-world conditions. This is where most life sciences organizations encounter the MLOps deficit.
Transitioning a model from a local notebook to a high-throughput clinical or research workflow exposes a range of engineering bottlenecks. Post-hoc explainability methods can introduce significant computational overhead, sometimes rendering them impractical for time-sensitive clinical workflows [5]. Infrastructure that was not designed for scale will fail at scale.
MLOps in life sciences is about creating a reliable engineering environment for scientific AI. A production-ready environment should include:
Data and model lineage Teams need to trace which data was used, how it was processed, which model version generated an output, and what assumptions were built into the workflow. This is essential for reproducibility and regulatory review.
Model drift monitoring Performance degrades when new data differs from the data used during development. In life sciences, this may happen because of a new assay protocol, a different patient cohort, a different instrument, or changes in data capture. Drift monitoring helps teams detect when a model may no longer be reliable [6].
Version control Scientific AI workflows involve multiple datasets, feature sets, model versions, and evaluation methods. Without proper version control, teams lose the ability to explain why one result differs from another.
Validation workflows A tool used for exploratory research does not need the same validation approach as a tool supporting clinical decision-making. Still, every use case needs clear acceptance criteria and a shared understanding of risk – aligned with GAMP 5 principles for regulated environments.
Scalable deployment A notebook proves that a method works. It cannot support a high-throughput workflow on its own. Production-grade AI systems need stable APIs, compute infrastructure, access controls, monitoring, and integration with tools already used by scientists, clinicians, or operational teams.
Without this engineering layer, AI remains fragile, impressive in a demo, but difficult to repeat, maintain, or trust.
Engineering for Trust: Beyond the Black Box
Trust in AI is often discussed through the lens of explainability. Explainability matters, especially when users need to understand why a model produced a specific output. But in life sciences, trust is broader than model interpretation.
There is a persistent tension between the accuracy of deep learning models and the requirement for Explainable AI (XAI) demanded by clinicians and regulators [5]. More importantly, even explainable models can fail in ways that are hard to detect.
Models can learn shortcuts: relying on site-specific tokens like scanner differences in radiology rather than actual pathology. In genomics, modest shifts in data distribution can trigger attribution flipping, completely altering which features the model considers important [5]. In those cases, the deeper issue is that the system may be answering the wrong question.
Engineering for trust means designing workflows that make these risks visible early. For end users, this requires:
- Transparent intended use
- Documented data provenance
- Validation against relevant benchmarks
- Uncertainty estimates where appropriate
- Human oversight and escalation paths
- Monitoring after deployment
The regulatory environment is reinforcing this direction. The FDA’s January 2025 draft guidance on AI-enabled medical devices and the EU AI Act – applicable from August 2026 – create an immediate mandate for auditability and risk control in AI drug discovery infrastructure and clinical AI systems alike. The UK MHRA’s AI Airlock sandbox offers one model for testing complex AI systems in a controlled, collaborative regulatory environment before full-scale deployment.
Shift-Left Governance: Build Compliance In, Not On
In many AI initiatives, data governance in pharma and life sciences appears too late in the process. A team builds a promising model, prepares a demo, and only then begins to ask how the system should be validated, documented, monitored, or approved for broader use. This sequence creates delays, rework, and sometimes the discovery that a technically strong model cannot be deployed at all.
Shift-left governance means embedding regulatory, ethical, quality, and risk considerations early in the development lifecycle, before the system becomes difficult to change. Strong data governance is what makes AI deployable in practice.
For life sciences organizations, shift-left governance includes:
- Defining the intended use of the AI system at the outset
- Classifying the risk level
- Identifying required documentation and validation criteria
- Deciding when human review is mandatory
- Planning how outputs will be monitored post-deployment
- Clarifying data access and privacy requirements
- Documenting who owns the system after deployment
The benefit is practical. Teams avoid building AI solutions that look technically promising but cannot be deployed because life sciences data infrastructure, validation, or governance requirements were not addressed in time [7].
Federated Learning and the Data Silo Problem
Data fragmentation is not always a problem that can be solved by centralizing everything. In many life sciences and healthcare contexts, patient privacy, data ownership, contractual restrictions, and security requirements limit how data can be combined across institutions or geographies.
Federated learning offers a reusable architectural pattern for this challenge: models learn from data distributed across different locations without requiring all data to be moved into one central repository. The MELLODDY project, which aggregated 2.6 billion data points across 10 pharmaceutical companies without sharing proprietary compound data, demonstrates that production-grade AI models can be trained on decentralized datasets at scale [10]. Platforms like Owkin’s federated learning infrastructure take a similar approach for clinical settings.
Related approaches, including secure multiparty computation, differential privacy, and trusted research environments, can further support cross-institutional collaboration while managing risk.
These approaches are not a universal solution. They introduce their own engineering complexity, governance requirements, and performance considerations. The broader principle, however, applies across all architectures: scalable AI infrastructure must reflect how data can actually be accessed, governed, and used.
Human-Centered Design: The Adoption Problem
Even technically strong AI systems fail when they do not fit the way people work. Scientists, clinicians, and operational teams do not need another disconnected dashboard. They need tools that reduce friction, support decisions, and respect the complexity of their workflows.
A critical element of successful deployment is positioning AI as a tool that augments expertise rather than replaces judgment. Organizations that engage early adopters, co-design interfaces with end users, and surface relevant context, model uncertainty, data quality indicators, confidence levels, alongside predictions build bottom-up momentum and reduce resistance [7].
Before building the model, teams should understand:
- What decision the user is trying to make
- What evidence they currently rely on
- Where the current workflow is slow or repetitive
- What level of uncertainty is acceptable
- What output format would be actionable
- When human review is required
- How the AI system will fit into existing tools
The goal is to make expert judgment faster, better informed, and easier to apply consistently.
A Practical Framework for Scaling AI in Life Sciences
Organizations that want to move from AI pilots to production should focus on the operating model around AI – not only on the next use case. The following five layers provide a practical foundation for scaling AI in life sciences.
Fig 1. Five layers needed to scale AI in life sciences
1. Data foundation Create reusable, well-described, quality-controlled data assets. Prioritize metadata, lineage, interoperability, and clear ownership. Treat important datasets as products that can support multiple use cases. This is the core of any robust life sciences data infrastructure.
2. Scientific and technical alignment Bring domain experts, data scientists, engineers, and product owners into the same workflow. AI in life sciences needs both biological relevance and engineering reliability. The shortage of professionals with genuine interdisciplinary expertise, combining AI engineering with biology, chemistry, or clinical research, remains one of the most significant constraints on scaling [1].
3. MLOps and platform capabilities Build reusable components for data pipelines, model training, evaluation, deployment, and monitoring. Avoid rebuilding infrastructure from scratch for every pilot. Top-performing organizations invest the early months defining platform blueprints, an upfront cost that accelerates every subsequent use case [8].
4. Governance and validation Define intended use, risk level, validation requirements, auditability, and human oversight early. Align with applicable regulatory frameworks. Make data governance in pharma and life sciences part of the development lifecycle, not a final checkpoint.
5. Adoption and workflow integration Design AI around the people who will use it. Integrate outputs into existing workflows, provide context, and make limitations visible.
This foundation may feel slower at the start. In practice, it accelerates everything that follows. Once data products, pipelines, governance patterns, and deployment workflows exist, new AI use cases become far easier to evaluate, build, and scale.
Slow Down to Speed Up
The most successful AI strategies in life sciences are rarely those that chase the highest number of pilots. They are the ones that build reusable foundations.
The era of AI experimentation is giving way to something more demanding: the engineering of production-grade AI solutions that can be maintained, monitored, and trusted over time. That requires investing early in life sciences data infrastructure, metadata quality, architecture, governance, and workflow design.
The organizations that scale AI effectively will know where their data comes from. They will know how their models are performing in production. They will know when human oversight is required. They will know which outputs are reliable enough to support decisions.
Most importantly, they will have built AI systems that can be reused, improved, and trusted across the full lifecycle.
Conclusion
Scaling AI in life sciences requires a shift from isolated experimentation to production-grade systems. Better models matter, but they are only one part of the equation. The real differentiator is the infrastructure that makes AI usable: computable data, robust MLOps in life sciences, shift-left governance, regulatory alignment, and human-centered workflows.
For life sciences teams planning their AI roadmap, the key question is not only what model to build next. The more important question is whether the organization has the life sciences data infrastructure, engineering workflows, and data governance needed to make AI reliable at scale.
If the answer is unclear, that is the right place to start.
Frequently Asked Questions
What does scaling AI in life sciences mean?
Scaling AI in life sciences means moving AI from isolated pilots or proof-of-concept projects into reliable workflows used across research, clinical, operational, or commercial teams. It requires life sciences data infrastructure, governance, validation, monitoring, and integration with real user workflows.
Why do many AI pilots fail to scale in life sciences?
Many AI pilots fail to scale because the surrounding infrastructure is not ready. Common barriers include fragmented data, weak metadata, limited lineage, unclear validation requirements, lack of MLOps in life sciences, poor integration with existing systems, and low user adoption.
What is AI-ready data?
AI-ready data is structured, well-described, quality-controlled, and usable by machines with minimal manual interpretation. In life sciences, AI-ready data also requires scientific context, metadata, provenance, and clear information about how the data was generated and transformed.
Why is MLOps important for life sciences AI?
MLOps in life sciences helps teams deploy, monitor, and maintain AI models in real-world conditions. It supports reproducibility, version control, model drift monitoring, validation, traceability, and controlled updates to AI workflows.
How can life sciences organizations build trust in AI systems?
Trust depends on more than explainability. Organizations need clear intended use, documented data provenance, validation against relevant benchmarks, uncertainty communication, human oversight, monitoring, and auditability. Users need to understand when an AI output is reliable and when it requires caution.
What is shift-left governance in AI development?
Shift-left governance means addressing risk, quality, regulatory, ethical, and validation requirements early in the AI development lifecycle. This approach – critical for data governance in pharma – helps teams avoid late-stage deployment delays and ensures that AI systems are designed with real-world use requirements in mind from the start.
Is federated learning useful for life sciences AI?
Federated learning can be valuable when data is distributed across institutions or cannot be centralized because of privacy, ownership, or regulatory constraints. Projects like MELLODDY demonstrate its potential at scale, though it also requires strong engineering, governance, and monitoring capabilities.
What regulatory frameworks apply to AI in life sciences?
Key frameworks include GAMP 5 for validated systems in regulated environments, the FDA’s 2025 draft guidance on AI-enabled medical devices, and the EU AI Act applicable from August 2026. The UK MHRA’s AI Airlock provides a sandbox environment for testing AI systems before full deployment.
Technical editing: Ardigen expert: Jan Majta, PhD
References
- Lyons P., Konersmann T., Jacobson S., Kleyn N., Rekhraj K., Gosalia D. 2026 Life Sciences Outlook. Deloitte Insights. 2025. Available from: https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html
- AI in biology and health: opportunities and challenges. High level roundtable discussion. EMBL. 2024. Available from: https://www.embl.org/documents/wp-content/uploads/2024/02/AI-in-biology-and-health-opportunities-and-challenges.pdf
- Liu T, Li W. Applications and challenges of artificial intelligence in life sciences. SHS Web Conf. 2024;187:04007. Available from: https://www.shs-conferences.org/articles/shsconf/abs/2024/07/shsconf_essc2024_04007/shsconf_essc2024_04007.html
- Factors hindering AI adoption in life sciences: 2023–2026. IntuitionLabs. 2025. Available from: https://intuitionlabs.ai/articles/ai-adoption-life-sciences-barriers
- Krejcar O, Abdullah J, Namazi H. Implementing XAI in life sciences: Key challenges and pathways to solutions. Artif Intell Life Sci. 2026;9(100153):100153. https://doi.org/10.1016/j.ailsci.2026.100153
- Scaling gen AI in the life sciences industry. McKinsey & Company. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/scaling-gen-ai-in-the-life-sciences-industry
- Conde H. Challenges and opportunities of implementing AI in the life sciences and pharmaceutical industries. LinkedIn. 2026. Available from: https://www.linkedin.com/pulse/challenges-opportunities-implementing-ai-life-sciences-hugo-conde-zq6ge/
- Wang T, Zhang X, Wang Y, Peng J. Recent progress and challenges of artificial intelligence in bioinformatics and new medicine. Applied Sciences. 2025;15(17):9598. https://doi.org/10.3390/app15179598
- Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. https://doi.org/10.1038/s41586-021-03819-2
- Simm J, Klambauer G, Arany A, et al. Splitting chemical structure data sets for federated privacy-preserving machine learning. Journal of Cheminformatics. 2021;13:96. https://doi.org/10.1186/s13321-021-00576-2
